Adverse events associated with azathioprine treatment in korean pediatric inflammatory bowel disease patients

Area of Science:

• Pediatric Gastroenterology
• Clinical Pharmacology
• Immunosuppressive Therapy

Background:

• Inflammatory bowel disease (IBD) management in pediatric populations often requires immunosuppressive agents.
• Azathioprine is a commonly used thiopurine drug for maintaining remission in pediatric IBD.
• Understanding the adverse event profile of azathioprine in Korean children is crucial for optimizing treatment.

Purpose of the Study:

• To determine the incidence and clinical course of adverse events linked to azathioprine therapy.
• To analyze the specific types of adverse reactions observed in Korean pediatric IBD patients.
• To provide data for informed clinical decision-making regarding azathioprine use.

Main Methods:

• Retrospective review of medical records for 174 pediatric IBD patients treated with azathioprine.
• Data collection spanned from January 2002 to December 2012 at Samsung Medical Center, Seoul, Korea.
• Adverse events, their management (dose reduction/discontinuation), and specific reactions were documented.

Main Results:

• Over half of patients (56.3%) experienced adverse events, leading to dose reduction in 17.8% and discontinuation in 10.3%.
• Bone marrow suppression, particularly leukopenia, was the most frequent adverse event (27.0%), necessitating dose reduction in 12.6% and discontinuation in 4.6%.
• Other significant adverse events included gastrointestinal disturbances (15.5%), hair loss (12.1%), and pancreatitis (7.5%).

Conclusions:

• Azathioprine treatment in Korean pediatric IBD patients is associated with a substantial frequency of adverse events, predominantly bone marrow suppression.
• The findings underscore the necessity for vigilant monitoring of pediatric patients receiving azathioprine for IBD.
• Early identification and management of adverse events are critical for safe and effective long-term therapy.